Epitalon + AOD-9604 Stack: Safety, Monitoring, and Dosing Protocol

What are Epitalon and AOD-9604?

Epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland. FDA treats epitalon and epithalamin as different substances, so studies of epithalamin are not studies of epitalon, and FDA says epitalon first appears to have been synthesized in 1999 [1].

AOD-9604 is a 16-amino-acid fragment of human growth hormone: hGH amino acids 177 to 191 with an extra tyrosine added at the N-terminus, which is why it is also sold as hGH fragment 176-191 [5]. It is not full-length growth hormone. An Australian company, Metabolic Pharmaceuticals, developed it as an anti-obesity drug candidate, and phase IIa trials were under way by February 2002; it never reached approval, and the obesity program was later dropped [2][3].

Is there an approved or tested dose for the stack?

Neither peptide has an approved dose [1][3].

For epitalon, websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles, with one site suggesting a course every four months; FDA treated those figures as marketing, not evidence [1]. The human studies FDA located used different regimens entirely: a sublingual spray delivering about 0.5 mg per day for 20 days, and an injection beside the eye in retinitis pigmentosa [1][7].

For AOD-9604, the one sizable human study was an oral anti-obesity drug candidate given for 24 weeks to 534 enrolled and 502 randomized participants, and it failed to show a significant benefit on the primary weight-loss endpoint [3]. That conclusion rests on sponsor-reported phase 2 results rather than a peer-reviewed trial report, and the review describing it notes there are no robust human data for visceral fat or other metabolic benefit [3]. Injected AOD-9604 sold online has no efficacy trials we found [3].

No study establishes a combined dose, cycle length, or washout period for Epitalon and AOD-9604. Schedules sold online are not evidence-based protocols [1][3].

What does FDA say about the safety of each peptide?

Epitalon. FDA found no clinical study that assessed epitalon's safety, and its search of the adverse-event database through December 8, 2025 and of the food and supplement complaint system through December 5, 2025 retrieved no epitalon reports [1]. One safety claim reported 'no side effects' without a dose, route or number of people [1]. For subcutaneous injection, FDA raised an immunogenicity concern related to peptide aggregation and impurities [4][1].

The mechanistic worry is cancer. Epitalon induced telomerase activity and telomere elongation in cultured human fetal fibroblasts that lack telomerase [8]. FDA warned that because it activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, epitalon has a mechanistic potential to be carcinogenic [1]. The mouse work on cancer and chromosome damage that FDA reviewed was too limited (one fixed dose, female mice only, short exposure) to show safety [1]. A separate published mouse study found that epitalon reduced the cumulative number and maximum size of mammary tumors in HER-2/neu transgenic mice dosed at 1 microgram per mouse for 5 consecutive days every month from age 2 months [9]. A 2026 review concluded that pharmacokinetic, dose-ranging and long-term safety data remain inadequate [10].

AOD-9604. FDA's page on bulk substances that may present significant safety risks when compounded states that FDA 'has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear,' and gives no details [4]. The same page flags immunogenicity risk for certain routes of administration from peptide impurities and characterization problems, and says FDA has identified no, or only limited, safety information [4]. A 2026 review of gray-market peptides found that many show favorable results in animals but rigorous human safety data are scarce and there is potential for serious harm [11].

Across growth-hormone-axis peptides generally, reported adverse effects in self-administered use include dysglycaemia, fluid retention, muscle and joint pain and injection-site reactions [3].

What monitoring is actually supported?

FDA found no clinical safety study of epitalon and no pharmacokinetic data for it [1]. We found no study that tested the two peptides together in people, so nothing in the evidence defines a monitoring plan for the combination [1][3]. For AOD-9604, the human evidence described is a sponsor-reported weight-loss trial that missed its primary endpoint, plus FDA's statement about possible serious adverse events with unclear causality [3][4].

The practical points that are documented:

• FDA's concerns include peptide impurities, characterization problems and possible immunogenicity for certain routes [4][1].
• Product composition, dose, and stacking practices in unregulated supply chains are uncertain, and rigorous human safety data for unapproved peptides are scarce [3][11].

Do the two peptides interact?

No pharmacokinetic data exist for epitalon, and we found no study that tested epitalon and AOD-9604 together in people [1][3].

The proposed mechanisms are different. Epitalon's telomere effect was shown in cell culture [8]. AOD-9604's fat-loss effects were shown in rodents: in obese Zucker rats, oral AOD9604 at 500 microgram/kg/day for 19 days cut body-weight gain to 15.8 g versus 35.6 g in controls and raised fat-tissue lipolytic activity, without the insulin-sensitivity harm seen with growth hormone [14]. In obese mice, 14 days of injected AOD9604 reduced body weight and fat, and long-term treatment failed to do so in mice lacking the beta-3 adrenergic receptor, although an acute dose still raised energy expenditure and fat oxidation in those animals [15]. Preclinical work found no growth-hormone-receptor binding [3].

Different targets do not establish that the pair is safe together. Whether AOD-9604 raises IGF-1 in people is also unresolved, because the human data are too limited to say [3]. The safety of combining AOD-9604 with other growth-hormone-axis peptides has not been established; dose and stacking practices in unregulated supply chains are uncertain, and rigorous human safety data are scarce [3].

What is each peptide's legal status in the US?

Epitalon is not an approved drug and is not a component of one. FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1]. It received an orphan drug designation for retinitis pigmentosa on September 2, 2010, which was withdrawn on January 6, 2016 [1].

It sits in the 'nominated but withdrawn' table on FDA's list of bulk substances that may present significant safety risks in compounding, where FDA states it has not identified safety-related information for the proposed route of administration [4]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or on FDA's list for outsourcing facilities (updated March 21, 2025) [16][17][18]. FDA staff proposed in July 2026 that neither epitalon free base nor epitalon acetate be added to the compounding bulks list, citing poor characterization, no clinical safety data, immunogenicity concern for subcutaneous injection, and the existence of approved insomnia drugs [1]. The Pharmacy Compounding Advisory Committee voted on July 24, 2026 in favor of adding it, against the staff recommendation; that vote is advice only and not binding, and epitalon is not on the list [13][12]. HHS's draft enforcement-discretion policy, filed October 28, 2026, names epitalon among six peptides and covers epitalon acetate given subcutaneously or intramuscularly in intermittent courses; it says HHS does not intend to take enforcement action against certain pharmacies and physicians if its conditions are met, and it is not an approval or a listing [12][19].

AOD-9604 is also unapproved and also sits in the 'nominated but withdrawn' table with the safety statements above [2][4]. It appears in none of the three categories on FDA's lists for state-licensed pharmacies and physicians or for outsourcing facilities, so the category 1 policy does not cover it [16][17][18]. It is not one of the six peptides named in HHS's October 2026 draft policy [12].

FDA's GRAS Notice Inventory contains no AOD-9604 notice, so FDA has not issued a no-questions letter for it [20].

Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness or quality before they reach patients [21].

Are either of them banned in sport?

AOD-9604 is. WADA's Prohibited List names AOD-9604 and hGH 176-191 in section S2.2.3 as growth hormone fragments, prohibited at all times in and out of competition, and it is on both the 2026 List and the 2027 List [6][22]. Anti-doping scientists have published urine detection methods for AOD-9604 and its stable metabolite [5].

Epitalon is not named in the 2026 or 2027 List [6][22]. Class S0 prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and gives BPC-157 only as an example; we found no WADA statement on whether epitalon falls under S0 [6][22].